Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And yet we are in low .20’s
I saw that too FUN but it seems since then a dump of the stock. And it continues. Guessing that a split is on the horizon after the dump is complete.
One news item I missed while camping at Lake George--->>>Aleafia Health Reports Strong 2021 Second Quarter Financial Results with 53% Sequential Increase in Cannabis Net Revenue
IMO, measured against a crappy prior Q, the percentage gain is terrific. In real numbers, we are waiting on the Q3 harvest to really determine if Aleafia has what it takes or is just another cannabis also-ran in need of finding a buyer, or shuttering the doors. Compared to MediPharm which appears to be a completely failed cannabis investment, Aleafia does seem to possess potential life. Q3 and Q4 are more critical than ever before.
Read the rest in a better format at this link:
https://aleafiahealth.com/news-releases/aleafia-health-reports-strong-2021-second-quarter-financial-results-with-53-sequential-increase-in-cannabis-net-revenue/
Darn it, I thought the Unifor deal would have made the market happy that is why I held.
I understand that the offer was never lower than my bid, but when a sell-at-the-market order is placed, how does it make any sense to fill that sell order at a bid lower than the highest bid? That’s trading thru the bid in my book. It’s the same thing as having an offer lower than the bid.
It’s MM games. It’s OTC games.
I would bet that the ask always stayed above your bid price of .291. Therefore, it was a "hit or miss" situation for you. You got over 1/2 the shares you wanted and some others were able to buy some shares at a bit lower price. Unfortunately, you don't have a leg to stand on if you were to contest it with your broker since your bid was lower than the ask.
I was .291 bid for 5,000 shares, limit order, today. I was filled in 2,931 shares at 2:30 CST. Then, the following trades occurred:
4,000 traded @ .2901 @ 2:31 CST
1,705 traded @ .29 @ 2:32 CST
300 traded @ .2901 @ 2:32 CST
1,447 traded @ .2907 @ 2:58 CST
Is there any valid explanation for why I didn’t get filled on my entire order?
Or do we chalk this up to “MM privilege” and the “OTC is the wild Wild West”?
Thx FUN but I think I'll be out of town then too. I'll have to check.
Aleafia Health to Announce 2021 Second Quarter Results
I hope it's not another disappointment:
https://mailchi.mp/aleafiahealth.com/aleafia-health-to-announce-2021-second-quarter-results?e=02506ded3e
I'll be camping at Lake George when they announce. - FUNMAN
Yup, plug that hole.
It sure feels like Aleafia sprung a slow leak.
Seems like good news but not much volume yet.
Aleafia Health Announces the Appointment of Mark J. Sandler as Board Chair
https://aleafiahealth.com/news-releases/aleafia-health-announces-the-appointment-of-mark-j-sandler-as-board-chair/
TORONTO, July 29, 2021 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) a global leader in cannabis wellness products and services, is pleased to announce the appointment of Mark J. Sandler as Chairman of its Board of Directors (the “Board”). He is the longest serving member of the Company’s board, which is composed entirely of independent directors, and chairs its Governance Committee.
Currently senior partner at Cooper, Sandler, Shime, & Bergman LLP, Mr. Sandler is a leading appellate and trial lawyer, as well as an adjudicator and mediator in regulatory matters, including securities litigation. He served three terms as an elected member of the Law Society of Ontario’s governing body.
“Aleafia Health is well positioned to continue on its growth trajectory of the last three years, from a pre-revenue startup to a leading global cannabis company,” said Mr. Sandler. “In supporting the objectives of the company, we will continue to prioritize strong corporate governance, and sustainable growth in the adult-use, medical and international markets.”
For Investor & Media Relations:
Nicholas Bergamini, VP Investor Relations
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and with sales and operations in Australia and Germany. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.
Aleafia Health owns four significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips, and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
I think the biggest question has to be about the union contract. Why does it appear to be doing nothing for the top and bottom line?
Regardless, it appears that we are waiting on the outdoor harvest again.
I thought the indoor cultivation facility was going to help flatten out the monthly revenues.
Something isn't going right?
I guess it might FUN and these folks have so many good things going on why does it remain wallowing down here.
Been gone a week. Closed on the camp and land.
Interesting--->>>Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application
I wonder if this can positively impact Aleafia's revenues? - FUNMAN
KetamineOne Capital Limited
Wed, July 28, 2021, 7:00 AM
5 min read
https://finance.yahoo.com/news/ketamine-one-advances-research-capabilities-110000639.html
The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health
VANCOUVER, British Columbia, July 28, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its wholly-owned contract research organization (“CRO”), KGK Science Inc., (“KGK”) has recently achieved several milestones in its psychedelic research capabilities and significantly expanded its access to patients through further integration with Ketamine One.
Controlled Drugs and Substances Dealer’s Licence:
KGK recently applied for a controlled drugs and substances dealer’s licence under Canada’s Narcotic Control Regulations governing the possession, distribution, sale, clinical studies of and research and development of controlled substances, including Psilocybin, Psilocin, Ketamine, MDMA, LSD, DMT, Mescaline, Salvinorin A, Harmaline and Harmalol.
Subject to the approval of Health Canada, the licence will effectively enable KGK to offer a turn-key solution for third parties to conduct clinical trials involving psychedelic molecules, while also authorizing KGK to act as a centralized distributor for large, multi-location clinical trials.
Pre-Qualification of Canadian Facilities for Clinical Trials:
Additionally, Ketamine One has completed the pre-qualification audits of its Canadian clinics with KGK to prepare for the use of the Company’s facilities in future clinical trials. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study. This direct access to patients and clinics is expected to differentiate KGK from other CROs by providing the opportunity to study patients with differing demographics across various populations, while also shortening recruitment timelines for studies.
The Company has been focused on a swift integration of the medical clinics that Ketamine One previously announced on May 7th as having been acquired from Canabo Medical Corporation, a wholly-owned subsidiary of Aleafia Health Inc. (TSX: AH) (“Aleafia”) together with its other recent acquisition of KGK announced on June 3rd.
Additionally, as previously announced on January 21, 2021, Unifor and Aleafia entered into an exclusive 10-year agreement to support union members, retirees and their eligible dependents that receive medical cannabis insurance coverage clinics through Unifor's collective bargaining agreements. To date, the clinic network has seen over 75,000 unique patients and has conducted extensive research in cannabinoid therapy as it relates to sleeping disorders, opioid reduction and other topics.
Management Commentary:
“Today’s announcements are further evidence of the synergies between our growing clinic network and our contract research offerings,” said Ketamine One’s Interim CEO, Adam Deffett. “KGK will now have the ability to utilize our clinic sites for future trials, gain access to a large patient database and, upon approval, have a narcotic dealers license.
Our goal is that these initiatives will also provide Ketamine One patients with breakthrough treatments through clinical trials and our clinical staff with experience and protocols needed for the eventual expansion of new treatments. We view this as a great opportunity to demonstrate their operational capabilities while also earning a new revenue stream from Ketamine One,” added Mr. Deffett.
General Research:
The Company has engaged General Research GmbH (“GR”) to increase its exposure to investors in Europe. The services agreement with GR has an aggregate cash cost of 40,000 Euros, has an initial term of two months, and such term may be extended for subsequent periods. GR will not receive any securities of the Company as compensation, and it does not currently own any securities of Ketamine One. Ketamine One and GR are unrelated and unaffiliated entities; GR is arm’s length to the Company.
ABOUT KETAMINE ONE
KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of 16 clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc. as the Company’s contract research division also places the company at the forefront of premium clinical research based on its 23-year history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.
On behalf of:
KETAMINE ONE
"Adam Deffett"
Adam Deffett, Interim CEO
For further information, please contact:
Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: www.ketamine.one
Twitter: @KetamineOne
Notice Regarding Forward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and future prospects of the Company.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.
Ya, I try to share her videos when I see them. She seems like she is just sharing her experience, I like that.
Imagine that; cannabis made a bit of a come back today.
And it looks like Aleafia is only going in one direction. Geeezzz, I bet on the wrong pony and am sorry I got others to join me.
Diogenes of Sinope Member Level Monday, 07/19/21 12:30:28 PM
Re: FUNMAN post# 3183
Post # 3185 of 3185
Well stated and agreed.
Looking forward to a strong sector rebound before I’m “planted”.
GL!
Well stated and agreed.
Looking forward to a strong sector rebound before I’m “planted”.
GL!
She made a few product review videos of Aleafia products. You and I are 2 of the 11 viewers so far.
happyglass Member Level Tuesday, 07/06/21 03:35:49 PM
Re: None
Post # 3180 of 3183
Video opinion on Noon & Night Aleafia’s new rollon cbd product. She says it helped :)
Diogenes, Let's hope someone gives a hoot. Moving forward introducing new brands is great, but without marketing, it's as if mgmt is just throwing the spaghetti at the wall and hoping it sticks as well as Grey Goose Vodka did, and they did a ton of marketing.
Better analogies are cigars and scotches. In an age where smoking is frowned upon it's tough to find a breakout success. Maybe Cohiba and Macanudo rings a bell with some people. Scotch brands are even more elusive. Maybe most people know of Jonnie Walker, but aficionados gravitate to single malts.
All I am saying is releasing great new strains that appeals to experienced cannabis aficionados isn't going to move the needle unless it's the "next Grey Goose".
Aleafia has to so more with social marketing. Other producers are doing it. Aleafia is pretty much ignoring brand building and creating demand.
I know there are advertising prohibitions, but other companies are doing it within the legal allowable parameters. Aleafia has to do more of it and get better at it.
Aleafia Health Launches Premium Cannabis Brand Nith & Grand
* Nith & Grand tailored to cannabis aficionados with discerning taste, and will feature craft flower and premium concentrates
* Initial launch features TF Pink Kush Live Resin vape cartridges
* Strengthened product portfolio contributing to meaningful quarterly
sales growth across all sales channels
TORONTO, July 19, 2021 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce the launch of its premium cannabis brand Nith & Grand.
Featuring hang dried, hand trimmed, small batch dried flower, and premium concentrates, Nith & Grand appeals to experienced cannabis aficionados.
The initial launch features TF Pink Kush Live Resin vape cartridges, which comprises a hydrocarbon extraction process utilizing fresh-frozen cannabis flower that preserves the strain’s natural flavour, aroma and terpene profile. The new product features the highly sought after and not yet widely available TF Pink Kush strain, and is now available in adult-use markets.
“Nith & Grand completes our highly differentiated brand portfolio, allowing us to reach the growing market for premium, craft cannabis products. With a collection of highly sought after cultivars and six years operating our craft cultivation facility in Paris, Ont., we are perfectly situated to delight cannabis connoisseurs,” said Aleafia Health CEO Geoffrey Benic.
“Aleafia Health can now boast one of the strongest and most diverse product portfolios in the Canadian cannabis industry. This along with scaling our production has directly led to strong sequential sales growth in the adult-use, wholesale, and medical sales channels, both domestically and internationally, in our most recent quarter.”
Nith & Grand’s namesake is a tribute to our product innovation facility’s home community of Paris, Ont., whose scenic downtown core is centred around the confluence of the Nith and Grand rivers.
For Investor & Media Relations:
Nicholas Bergamini, VP Investor Relations
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and with sales and operations in Australia and Germany. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.
Aleafia Health owns four significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips, and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Aleafia Health Launches Premium Cannabis Brand Nith & Grand
https://www.globenewswire.com/news-release/2021/07/19/2264756/0/en/Aleafia-Health-Launches-Premium-Cannabis-Brand-Nith-Grand.html
This is big
+A A -A Alto contraste
COVID-19
Literatura global sobre doença de coronavírus
??????? ?? (??) english français ??????? español português
Notícias/Atualização/Ajuda
Busca Avançada
Pesquisar
Home
Pesquisa
Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response
Este artigo é um Preprint
Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response
Dongbo Yang; Long Chi Nguyen; Vlad Nicolaescu; Thomas Best; Shaonong Chen; J. Brent Friesen; Nir Drayman; Adil Mohamed; Christopher Dann; Diane Silva; Haley Gula; Krysten A. Jones; J. Michael Millis; Bryan C. Dickinson; Savas Tay; Scott A. Oakes; Guido F. Pauli; David O. Meltzer; Glenn Randall; Marsha Rich Rosner.
Preprint | bioRxiv | ID: ppbiorxiv-432967
ABSTRACT
The rapid spread of COVID-19 underscores the need for new treatments. Here we report that cannabidiol (CBD), a compound produced by the cannabis plant, inhibits SARS-CoV-2 infection. CBD and its metabolite, 7-OH-CBD, but not congeneric cannabinoids, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after cellular infection, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD induces interferon expression and up-regulates its antiviral signaling pathway. A cohort of human patients previously taking CBD had significantly lower SARS-CoV-2 infection incidence of up to an order of magnitude relative to matched pairs or the general population. This study highlights CBD, and its active metabolite, 7-OH-CBD, as potential preventative agents and therapeutic treatments for SARS-CoV-2 at early stages of infection.
Video opinion on Noon & Night Aleafia’s new rollon cbd product. She says it helped :)
I do not think you will have to wait much longer :)
Don’t get me wrong. I’ve been trying to stay positive since 2017 but it only get’s worst and worst. I have five figures invested and been trying to recover at least $15k. No luck yet
I’m trying to stay positive.
Realistically, I’m in the red but add as I please as faith for future growth (even if undeserved) remains.
GLTA
Only with this stock! PR comes in and it drops
Aleafia Health Announces Results of Annual General Meeting
Aleafia Health Inc.
Tue, June 29, 2021, 8:15 AM EDT·5 min read
ALEAF
-5.05%
TORONTO, June 29, 2021 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”), a global leader in cannabis wellness products and services, is pleased to announce the results of the vote on the election of directors at its annual meeting of shareholders held on June 28, 2021 (the “Meeting”). All seven nominees set out in the management information circular of the Company dated May 20, 2021 were elected to the board of directors (the “Board”) of the Company.
Nominee
Votes in
Favour
Votes in
Favour as % of
Votes Cast
Votes Withheld
Votes Withheld
as % of Votes
Cast
Lea Ray
50,166,148
88.94%
6,236,810
11.06%
Mark Sandler
50,116,911
88.86%
6,286,047
11.14%
Loreto Grimaldi
50,186,704
88.98%
6,216,254
11.02%
Luciano Galasso
50,558,413
89.64%
5,844,545
10.36%
Carlo Sistilli
50,541,623
89.61%
5,861,335
10.39%
Michael LeClair
50,554,433
89.63%
5,848,525
10.37%
Ian Troop
50,534,824
89.60%
5,868,134
10.40%
Final voting results on all matters will be filed on the Company’s SEDAR profile at www.sedar.com.
The Company welcomes two newly elected independent directors, Ian Troop and Michael LeClair. Mr. LeClair is an experienced director in the for-profit and not-for profit sectors in Canada and strategic advisor with an extensive senior leadership background in corporate finance, private equity and mergers & acquisitions. He currently serves as the chair of the board of independent trustees of Centurion Financial Trust, and as a member of the board and audit committee chair of a publicly traded natural food company. Previously, Mr. LeClair was a managing director of the private debt group for TSX listed Integrated Asset Management, a leader in the alternative investment sector with $2.4 billion in assets under management at that time.
- ADVERTISEMENT -
Mr. Troop is a seasoned executive and business leader in the for-profit and not-for-profit sectors in Canada and globally. His career is highlighted by 20 years at Procter & Gamble leading business divisions in Mexico, Poland and North America. He was the CEO of the successful 2015 Parapan American Games hosted in Toronto, which remains the largest sporting event in Canadian history. Mr. Troop was appointed as Operating Advisor to the private equity group of OMERS, one of Canada’s largest pension funds.
Additionally, the Company announces today that Lea Ray and Loreto Grimaldi have indicated their intention to resign from the Board. Their resignations will take effect following a transition period expected to be no more than 30 days following, during which time they will continue as members of the Board.
The Company wishes to thank Ms. Ray and Mr. Grimaldi for their service, leadership and dedication, as two of Aleafia Health’s longest serving board members.
Aleafia Health also announces today that the Board has determined to appoint Jon Pereira as an independent director of the Company. Mr. Pereira will join the Board concurrently with the effectiveness of Ms. Ray and Mr. Grimaldi’s resignations.
Mr. Pereira brings a wealth of operations and executive management experience gained from previously held positions in the electronics manufacturing space and board service. A respected Canadian entrepreneur, he co-founded Olympic Circuits which was later acquired by a U.S. publicly traded company. Mr. Pereira led the integration and continued to serve as president of a key business unit managing over 8000 employees and generating revenue in excess of USD$800 million spanning global markets across North America, Asia and Europe. Throughout his career, Mr. Pereira has led with a strong focus on operational efficiency, cost management and strategic business development. He received a Bachelor of Chemical Engineering from the University of Toronto.
For Investor & Media Relations:
Nicholas Bergamini, VP Investor Relations
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and with sales and operations in Australia and Germany. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.
Aleafia Health owns four significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips, and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
To follow up, I was up until 3am and had yet to feel the effects. It takes a long time for edibles to hit for me. I slept very well lol! I will try another time, earlier in the day and report on how it feels :)
To follow up, I was up until 3am and had yet to feel the effects. It takes a long time for edibles to hit for me. I slept very well lol! I will try another time, earlier in the day and report on how it feels :)
They are delicious. I am eating them right now. The pretzels are small, about 1 inch square and the caramel in between is creamy and chewy but not tooth grabbing like toffee. There is a slight weed undertone but it is not bad at all. I will let you know what the effect is (if I stay awake that long) I am happy with them. Not good for gluten free folks but the kitchen has other products for them
Aleafia Health Expands Bogart's Kitchen Edibles Portfolio with Launch of Salted Caramel Pretzel Bites
Thanks Diogenes,
This could be a problem for me in combination with beer. - FUNMAN
https://mailchi.mp/aleafiahealth.com/aleafia-health-expands-bogarts-kitchen-edibles-portfolio-with-launch-of-salted-caramel-pretzel-bites?e=02506ded3e
Yeah I know FUN. And it was a beautiful day too. 73 degrees and a nice breeze.
I love the smell of grass
Out mowin the lawn and puttin the robot in the pool to clean where I just was. Lol.
Where's Reddit when you need them?
$oldier Hard Member Level Wednesday, 06/23/21 01:04:10 PM
Re: FUNMAN post# 3162
Post # 3165 of 3165
Like you FUN I'm also a bit skeptical, so I wait and watch.
Like you FUN I'm also a bit skeptical, so I wait and watch.
Hilarity abounds.
lecorb Wednesday, 06/23/21 12:18:16 PM
Re: FUNMAN post# 3162 0
Post #
3163
of 3163
ALEAFIA HEALTH (OTCMKTS:ALEAF) PRICE TARGET AND CONSENSUS RATING
1 Wall Street analysts have issued ratings and price targets for Aleafia Health in the last 12 months. Their average twelve-month price target is $5.81, predicting that the stock has a possible upside of 1,686.04%. The high price target for ALEAF is $5.81 and the low price target for ALEAF is $5.81.
6/14/2021 Cantor Fitzgerald Lower Price Target Neutral ? Reduce $7.06 ? $5.81
MarketBeat.
Aleafia Health (OTCMKTS:ALEAF) had its price target cut by Cantor Fitzgerald from $7.06 to $5.81 in a report released on Monday. The firm currently has a “reduce” rating on the stock.
Shares of ALEAF stock traded down $0.00 during trading on Monday, reaching $0.35. 150,800 shares of the company’s stock were exchanged, compared to its average volume of 418,914. Aleafia Health has a twelve month low of $0.29 and a twelve month high of $1.07. The business has a fifty day moving average price of $0.40.
https://www.americanbankingnews.com/2021/06/14/aleafia-health-otcmktsaleaf-pt-lowered-to-5-81.html
BIG VOLCANO!
ALEAFIA HEALTH (OTCMKTS:ALEAF) PRICE TARGET AND CONSENSUS RATING
1 Wall Street analysts have issued ratings and price targets for Aleafia Health in the last 12 months. Their average twelve-month price target is $5.81, predicting that the stock has a possible upside of 1,686.04%. The high price target for ALEAF is $5.81 and the low price target for ALEAF is $5.81.
6/14/2021 Cantor Fitzgerald Lower Price Target Neutral ? Reduce $7.06 ? $5.81
MarketBeat.
Aleafia Health (OTCMKTS:ALEAF) had its price target cut by Cantor Fitzgerald from $7.06 to $5.81 in a report released on Monday. The firm currently has a “reduce” rating on the stock.
Shares of ALEAF stock traded down $0.00 during trading on Monday, reaching $0.35. 150,800 shares of the company’s stock were exchanged, compared to its average volume of 418,914. Aleafia Health has a twelve month low of $0.29 and a twelve month high of $1.07. The business has a fifty day moving average price of $0.40.
https://www.americanbankingnews.com/2021/06/14/aleafia-health-otcmktsaleaf-pt-lowered-to-5-81.html
BIG VOLCANO!
Until mgmt provides more color on what's happening with the union/insurance/tie-in-to-revenues, IMO nothing is happening.
Especially after the last ER. They should not have been impacted one little bit by the Canadian shutdown. Mail order was working just fine.
It's one thing to announce a deal, and a wholly different thing to execute on the potential and turn it into quantifiable revenues.
3 people in my family tried the Noon&Night CBD rollerball and they all got relief. 2 with back and neck pain and 1 with migraine. I like Aleafia more and more every day. The price as a patient is in the $20 range and the bottle is a decent size and it smells really nice.
Thanks Diogenes --->>> Aleafia Health Appoints Finance Executive Matt Sale as Chief Financial Officer
When anyone finishes reading this does anyone say "WOW"? - FUNMAN
COMPARISON ALEAFIA VS TILT HOLDINGS
Aleafia ALEAF
Last quarterly revenue $7.07M
Adjusted EBITDA $3.03M
Shares outstanding 330,491,826
Net loss/gain <$11,248,000>
Cash and cash equivalent $17.68M
Price per share $0.33
TILT Holdings TLLTF
Last quarterly revenue $46.8M
Adjusted EBITDA $6.2M
Shares outstanding 325,668,294
Net loss/gain <$1,500,000>
Cash and cash equivalent $9M
Price per share $0.50
Marketwatch
Cash & Short Term Investments
Quarter ended Mar 31st 2021
17.68M
Followers
|
85
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3371
|
Created
|
12/08/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |